763results about "Viruses" patented technology

The present invention relates to the field of genetic engineering. Specifically, the present invention relates to cytosine deaminase and use thereof in base editing. More specifically, the present invention relates to a base editing system based on a newly identified cytosine deaminase, a method for base editing a target sequence in the genome of an organism (e.g., a plant) using the base editing system, and a genetically modified organism (e.g., a plant) produced by the method and progenies thereof.

The invention relates to the field of gene engineering. In particular, the present invention relates to cytosine deaminases and their use in base editing. More specifically, the invention relates to a method for screening and identifying a deaminase, a base editing system based on a newly identified cytosine deaminase, a method for editing a target sequence in a genome of an organism (such as a plant) by using the base editing system, and a method for screening and identifying the target sequence. As well as genetically modified organisms (e.g., plants) and progeny thereof produced by the method.

The invention relates to the technical field of medicine screening, in particular to an active substance screening platform and application thereof. The active substance screening platform comprises a cell combination; the cell combination comprises immunoregulation screening cells and antioxidant screening cells; the immunoregulation screening cell is a mouse mononuclear macrophage RAW 264.7 carrying an NF-kappa B element conserved sequence and a reporter gene; the antioxidant screening cell is a porcine small intestine epithelial cell IPEC-J2 cell carrying an ARE element conserved sequence and a reporter gene. The invention provides a screening platform based on a specific cell combination, which can quickly obtain an active substance with immune regulation, antioxidation or two functions from a large number of candidate active substances, has the advantages of low cost and high efficiency, and has important application value.

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

Disclosed herein are an engineered immune cell with CIITA gene knock-out and use thereof. According to the present invention, an sgRNA specifically targeting CIITA gene is designed and synthesized, which can accurately target CIITA gene to achieve gene knock-out with high knockout efficiency. The provided sgRNA can be used for preparing a universal CAR-T cell.

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Disclosed are antigen-binding molecules, chimeric receptors, and engineered immune cells according to the present invention. The present invention also relates to vectors, compositions, and treatment and / or detection methods using the antigen-binding molecules and engineered immune cells.

To provide universal antigen presenting cells.SOLUTION: Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.SELECTED DRAWING: Figure 1A

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

To provide immunotherapy that prevents or minimizes the failure of immunotherapy treatment due to the emergence of antigen-loss escape mutations in cancer cells, etc. [Solution] A bispecific chimeric antigen receptor comprising (a) an antigen-specific target-directed region containing an antigen-specific single-chain Fv(scFv) fragment that binds to at least two different antigens, (b) an extracellular spacer domain, (c) a transmembrane domain, (d) at least one costimulatory domain, and (e) an intracellular signaling domain, which is to be co-expressed with a therapeutic regulatory substance such as truncated epidermal growth factor receptor (EGFRt).

To provide proteins for enhancing proliferation and / or healing and / or inhibiting apoptosis of non-transformed tissue or non-transformed cells.SOLUTION: The present invention provides proteins comprising amino acid sequences encoded by nucleic acids derived from a human chromosomal region C19Orf10 termed Factor 1 and / or C19Orf63 termed Factor 2, or inhibitors thereof. Further provided is use of inhibitors of Factor 1 and Factor 2 for medical use, preferably for use in treating or preventing a disease in which angiogenesis contributes to disease development or progression.SELECTED DRAWING: None

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present application discloses a use of an antigen short peptide in the screening of a drug for treating an HPV-related disease, and a T cell receptor (TCR) screened by the antigen short peptide. An amino acid sequence of the antigen short peptide is represented by SEQ ID NO: 1. The antigen short peptide of the present application can screen a specific TCR, T cells transduced with the TCR can be specifically activated and have a strong killing effect on tumor cells which express A1101 and HPV, and the TCR can be used for immunotherapy of HPV-positive tumors such as cervical cancer. Moreover, the T cells transduced with the TCR of the present application have a strong activation reaction on a cell line which expresses E7, have no activation reaction on a cell line which does not express E7, have a very strong killing function on the cell line which expresses E7, and can effectively inhibit the growth of E7-positive tumors.

Compositions and methods are described for delivering recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of human subjects diagnosed with Mucopolysaccharidosis Type II (MPS II).

The present invention relates to a recombinantly constructed protein that is useful for analytical assay, particularly for determining the presence of rhabdovirus specific antibody in biological samples obtained from individuals.More specifically, the present invention relates to a polypeptide that comprises the ectodomain of rhabdovirus glycoprotein and the heterologous multimerization domain connected to said ectodomain.In one example, there is provided a fusion protein of formula xyz (wherein x consists of or comprises the ectodomain, which may not contain furin cleavage site, y is a linker site, and z is the heterologous multimerization domain that may be selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence and avidin sequence).

The present application relates to scaffolds for treating solid tumor cells and evasion variants. Implantable stents are described that treat solid tumors and evasion variants and provide effective vaccination against cancer recurrence. The scaffold includes a genetically reprogrammed lymphocyte and a lymphocyte activating portion.

Anti-GCC single domain antibodies (e.g., VHH domain antibodies) and chimeric antigen receptors (CARs) that bind to GCC are provided, wherein the chimeric antigen receptors (CARs) comprise the anti-GCC single domain antibody in an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. Immune cells transduced with the disclosed CAR constructs and / or chimeric receptors can be used in cancer immunotherapy.

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present disclosure relates to a method for the production of CD4 + CD4 produced by genetically modifying T cells IL-10 / CAR Provide cell populations (autologous or allogeneic single donor and allogeneic polydonor). In addition, CD4 IL-10 / CAR Methods for generating CD4 cells and for immune tolerance IL-10 / CAR Methods of using the cells to treat GvHD, cell and organ transplantation, cancer, and other autoimmune and inflammatory disorders are provided.

The present invention relates to the field of bioengineering, and in particular to a CAR (chimeric antigen receptor) expression vector and an application thereof. The CAR expression vector comprises a

Provided are an antibody specifically binding to CD276 and use thereof. Specifically provided are a CD276 antibody or an antigen binding fragment thereof, and the like. Also provided are a polynucleotide encoding the CD276 antibody, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a preparation method and a transformed cell thereof. The provided CD276 antibody can bind to CD276 protein at a high affinity and a high specificity, can be prepared into a target recognition domain of CAR-T cells, and can also be prepared into a bispecific T-cell engager (BiTE) to exert an anti-tumor effect for preventing or treating cancers.

Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and / or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and / or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region. The therapeutic agent achieves synergistic therapeutic effect.

The invention provides a method for introducing an exogenous substance into a cell, the method comprising exposing the cell to a transient pressure reduction in the presence of the exogenous substance. Apparatus for performing the method of the invention is also provided.

The present invention pertains to: a granzyme B variant having enhanced protease activity and / or enhanced tolerance against an inhibitory factor; a polynucleotide encoding the granzyme B variant; a cell expressing the granzyme B variant; a pharmaceutical composition comprising the cell expressing the granzyme B variant; and a pharmaceutical composition comprising the granzyme B variant. In some embodiments, the pharmaceutical composition can be used in combination with a cell expressing a chimeric receptor and / or an antigen-binding molecule.